No profile data available.
Aprea Therapeutics, Inc. (APRE) is a healthcare company in the additional cancer treatment drugs industry, based in Doylestown, United States, with about 8 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$12.60 million. Its market capitalization was $7.61 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Aprea Therapeutics reported $0 in revenue for fiscal year 2025.
$7.61 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Moleculin Biotech, Inc. (MBRX), Bolt Biotherapeutics, Inc. (BOLT), CNS Pharmaceuticals, Inc. (CNSP), Traws Pharma, Inc. (TRAW).